New strategy aims to enhance efficacy and safety of bone repair treatment

Bone morphogenetic protein-2 (BMP2) is used clinically to promote bone repair. However, the high BMP2 concentrations required to stimulate bone growth in humans may produce life-threatening adverse effects, a problem that prompted an FDA warning in 2008. Now, a team of clinicians and engineers has shown that adding the protein kinase C-binding protein NELL-1 (Nel-like molecule-1) to BMP2 therapy may allow clinicians to achieve better results at lower — and safer — BMP2 doses. —> Read More